{"id":3201,"date":"2017-10-20T11:22:58","date_gmt":"2017-10-20T15:22:58","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=3201"},"modified":"2017-10-20T11:53:55","modified_gmt":"2017-10-20T15:53:55","slug":"ablynx-nv-ablx-ipo-preview","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/ablynx-nv-ablx-ipo-preview\/","title":{"rendered":"Ablynx NV ($ABLX) #IPO Preview"},"content":{"rendered":"

\"Ablynxlogo\"<\/a><\/p>\n

Company: Ablynx NV
\nSymbol: ABLX
\nDescription: They are a late-stage clinical biopharmaceutical company utilizing our proprietary Nanobody platform to develop treatments for a broad range of therapeutic indications with an unmet medical need.
\nShares: 9.17 million
\nPrice Range: $19.08-$19.08
\nTrade Date: 10\/25
\nUnderwriter(s): BofA Merrill Lynch, J.P. Morgan, Jefferies
\nCo-Manager(s): Baird, Bryan Garnier & Co., Ladenburg Thalmann
\nTerms Added: 10-17-17<\/p>\n

NOTE:\u00a0Their ordinary shares are listed on Euronext Brussels under the symbol ‘ABLX’.<\/em><\/p>\n

Link to F-1\/A Prospectus<\/a><\/strong><\/p>\n

Link to Retail Roadshow<\/a><\/strong><\/p>\n

Business<\/strong>:\u00a0They believe that Nanobodies represent a leading next generation protein therapeutic technology.They have more than 45 proprietary and partnered Nanobody programs across a range of therapeutic indications including hematology, inflammation, infectious disease, autoimmune disease, oncology and immuno-oncology.\u00a0Their\u00a0lead, wholly owned product candidate, caplacizumab, for the treatment of acquired thrombotic thrombocytopenic purpura, or aTTP, is currently undergoing regulatory review in Europe, and they\u00a0recently announced positive top line results from a Phase III trial with caplacizumab in October 2017. Submission of a Biologics License Application for caplacizumab in the United States is planned in the first half of 2018 and they received Fast Track Designation from the FDA for caplacizumab in July 2017. Their\u00a0wholly owned and partnered product pipeline includes three other Nanobody-based product candidates at the Phase II stage of development and four at the Phase\u00a0I stage of development, and they and their partners are currently planning to initiate Phase I trials for multiple other product candidates over the next few years.<\/p>\n

\"ablynxdrugs\"<\/a><\/p>\n

Collaborations & License Agreement:\u00a0<\/strong><\/p>\n

Merck\u00a0& Co., Inc. \u00a0<\/i><\/b>In October 2012, February 2014 and June 2017 they entered into a collaboration with Merck & Co or subsidiaries of Merck & Co. In 2012 they received\u00a0a \u20ac6.5\u00a0million upfront payment and a \u20ac2.0\u00a0million fee for research funding. In addition, subject to achieving the milestones specified in the agreement, they\u00a0are eligible to receive up to \u20ac429.0\u00a0million in milestone payments.\u00a0In February\u00a02014, they\u00a0received an upfront payment of \u20ac20.0\u00a0million and are eligible to accrue as much as \u20ac1.7 billion plus tiered percentage royalties.\u00a0In June 2017, they received another \u20ac2.5\u00a0million in a milestone payment under this collaboration. In addition, they are\u00a0eligible to receive up to \u20ac338.5 million in development and commercial payments per each program, totaling up to \u20ac486.0\u00a0million in development milestones and \u20ac3.57\u00a0billion in commercial milestones in the aggregate for all the programs covered by the agreement.<\/p>\n

AbbVie <\/i><\/b><\/p>\n

In September 2013, they entered into a global license agreement with AbbVie, Inc., or AbbVie. Under the agreement, they are eligible to receive, subject to achieving the milestones specified in the agreement, up to an aggregate of $415.0\u00a0million in regulatory milestones and $150.0\u00a0million in commercial milestones, plus double-digit royalties, relating to the development and commercialization of the anti-IL-6R Nanobody, vobarilizumab, in both RA and SLE. As part of the agreement, they received a $175.0 million upfront payment and assumed responsibility for the execution of Phase II clinical development for vobarilizumab in both RA and SLE.<\/p>\n

Boehringer Ingelheim <\/i><\/b><\/p>\n

In September 2007, they announced a strategic alliance with Boehringer Ingelheim International GmbH, or B.I., to discover, develop and commercialize up to 10 different Nanobody therapeutics. They received\u00a0\u20ac42.9\u00a0million in upfront payments, license fees and FTE payments during the research term of the agreement.<\/p>\n

Merck KGaA \u00a0<\/i><\/b>In September 2008, they entered into an agreement with Merck Serono, a division of Merck KGaA, to co-discover and co-develop Nanobodies against two therapeutic targets. In 2013, they announced that Merck Serono had initiated a Phase I trial with an anti-Il-17A\/F Nanobody arising from this agreement and this resulted in a \u20ac2.5\u00a0million milestone payment being paid to us.\u00a0In November 2011, we signed another agreement with Merck KGaA, to co-discover and develop Nanobodies against two targets in osteoarthritis and received a \u20ac20.0\u00a0million upfront payment. In May 2017, they announced that Merck KGaA had accepted the pre-clinical package for the first Nanobody under this agreement and this triggered the payment of a \u20ac15.0\u00a0million milestone payment to them.<\/p>\n

Sanofi S.A. <\/i><\/b><\/p>\n

In July 2017, they entered into a research collaboration and global exclusive licensing agreement with Sanofi initially focused on developing and commercializing Nanobody-based therapeutics for the treatment of various immune-mediated inflammatory diseases. The financial terms include an upfront payment of \u20ac23.0 million to them, comprised of license and option fees. In addition, Ablynx will receive research funding, estimated to amount to \u20ac8.0 million for the initially selected targets.<\/p>\n

Sector Performance:<\/strong> Offerings with cash raises of $25m+ on the list<\/p>\n

\"HealthcareSector10.20.17\"<\/a><\/p>\n

Book-Building Status<\/strong>: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.<\/p>\n

IPO Boutique subscription clients receive daily updates on this critical information.<\/a><\/p>\n

Conclusion<\/strong>: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a\u00a0track record<\/a>\u00a0with our performance for last 12 years at our website.<\/p>\n

Indicate with confidence,\u00a0SUBSCRIBE<\/a>\u00a0today.<\/p>\n","protected":false},"excerpt":{"rendered":"

Company: Ablynx NV Symbol: ABLX Description: They are a late-stage clinical biopharmaceutical company utilizing our proprietary Nanobody platform to develop treatments for a broad range of therapeutic indications with an unmet medical need. Shares: 9.17 million Price Range: $19.08-$19.08 Trade Date: 10\/25 Underwriter(s): BofA Merrill Lynch, J.P. Morgan, Jefferies Co-Manager(s): Baird, Bryan Garnier & Co.,[…]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[24],"tags":[1389],"class_list":["post-3201","post","type-post","status-publish","format-standard","hentry","category-ipo","tag-ablx"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3201","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=3201"}],"version-history":[{"count":2,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3201\/revisions"}],"predecessor-version":[{"id":3207,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3201\/revisions\/3207"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=3201"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=3201"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=3201"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}